Eledon announces dosing of 10th patient in Phase 1b trial of tegoprubart

Eledon Pharmaceuticals announced the dosing of the 10th patient in the Company’s ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation and will report interim clinical data from this study at the American Society of Nephrology, ASN, Kidney Week Annual Meeting in November 2023. “We are pleased with the strong pace of enrollment in our Phase 1b trial and believe it speaks to the underlying demand for a new and better immunosuppressive regimen for the thousands of patients each year who undergo kidney transplantation,” said David-Alexandre C. Gros, M.D., Chief Executive Officer. “This achievement represents the first successful clinical milestone in our recent financing agreement and positions us well to close the second tranche of funding upon the dosing of the 12th patient in our Phase 2 BESTOW study. We are activating sites in the BESTOW study and look forward to beginning enrollment.”